Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE M 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE M 75.
HYPAQUE vs HYPAQUE-M,75%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque (diatrizoate sodium/diatrizoate meglumine) is an ionic, high-osmolar iodinated contrast agent. It attenuates X-rays by increasing the atomic density in tissues, providing radiographic contrast. It is not pharmacologically active but may cause physiological effects due to hyperosmolality.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Intravenous: 50-300 mL of 30-60% solution depending on procedure; maximum 5 mL/kg. Intra-arterial: 5-80 mL per injection. Intrathecal: Not recommended due to neurotoxicity.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
None Documented
None Documented
The terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged and may exceed 20 hours in severe cases, requiring dose adjustment.
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
The drug is excreted unchanged primarily by the kidneys via glomerular filtration. Renal excretion accounts for >95% of elimination; biliary/fecal excretion is negligible (<5%).
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent